(NASDAQ: ARWR) Arrowhead Pharmaceuticals's forecast annual revenue growth rate of 97.18% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.02%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.75%.
Arrowhead Pharmaceuticals's revenue in 2024 is $35,473,000.On average, 8 Wall Street analysts forecast ARWR's revenue for 2024 to be $16,103,305,021, with the lowest ARWR revenue forecast at $440,910,817, and the highest ARWR revenue forecast at $37,508,469,460. On average, 7 Wall Street analysts forecast ARWR's revenue for 2025 to be $28,841,404,810, with the lowest ARWR revenue forecast at $2,484,004,600, and the highest ARWR revenue forecast at $65,764,021,785.
In 2026, ARWR is forecast to generate $31,536,798,201 in revenue, with the lowest revenue forecast at $24,156,944,735 and the highest revenue forecast at $43,507,340,569.